Experience of a diagnosis of advanced melanoma: The perspective of bereaved family carers

• Register: ANZCTR
• Last refreshed on: 13 January 2020
• Main ID: ACTRN12616001667404
• Date of registration: 02/12/2016
• Prospective Registration: No
• Primary sponsor: Queensland University of Technology
• Public title: Experience of a diagnosis of advanced melanoma: The perspective of bereaved family carers
• Scientific title: A changing treatment paradigm: Bereaved family carers' perspectives of supportive and palliative care needs in advanced melanoma
• Date of first enrolment: 30/05/2016
• Target sample size: 24
• Recruitment status: Completed
• URL: https://anzctr.org.au/ACTRN12616001667404.aspx
• Study type: Observational
• Study design: Purpose: Psychosocial;Duration: Cross-sectional;Selection: Convenience sample;Timing: Prospective;
• Phase: Not Applicable

Countries of recruitment

Australia

Contacts

• Name: Dr Jenny Fox

• Name: Dr Jenny Fox

Key inclusion & exclusion criteria

Inclusion criteria: Being a bereaved family carer who provided the majority of care for a person who died 2 to 18 months previously as a result of melanoma; being a bereaved family carer of person who received treatment at Peter MacCallum Cancer Centre, Melanoma Institute of Australia or Princess Alexandra Hospital; and being 18 years or older and English speaking.
Exclusion criteria: Bereaved carers who indicate they do not wish to participate.

Age minimum: 18 Years
Age maximum: No limit
Gender: Both males and females

Health Condition(s) or Problem(s) studied

Advanced melanoma;
Advanced melanoma

Cancer - Malignant melanoma

Intervention(s)

This study explores the experiences of bereaved family carers of persons who died as a result of advanced melanoma. The study uses in-depth interviews to examine the issues from the carer perspective. Single interviews will be conducted and will range in duration from 30 minutes to 90 minutes.

Primary Outcome(s)

Gain an in-depth understanding of experiences of health service provision of bereaved carers of patients with advanced melanoma from across three health care settings by carer interview. [One off Interview per carer will be conducted 2 to 18 months post bereavement.]

The ability of health care services to meet the support needs of patients and family carers will be determined by carer interview.[One off Interview per carer will be conducted 2 to 18 months post bereavement.]

Secondary Outcome(s)

Elements and processes of service provision that contribute to an effective model of support are identified through carer interview.[One off Interview per carer will be conducted 2 to 18 months post bereavement.]

Secondary ID(s)

Nil

Source(s) of Monetary Support

Sigma Theta Tau International

Ethics review

Status: Approved
Approval date:
Contact:

Melanoma Institute of Australia

Status: Approved
Approval date:
Contact:

Metro South Human Research Ethics Committee

Status: Approved
Approval date:
Contact:

Peter MacCallu,m Cancer Centre

Status: Approved
Approval date:
Contact:

Queensland University of Technology